July 17, 2026
3 min watch
Add topic to email alerts
Receive an email when new articles are posted on
Please provide your email address to receive an email when new articles are posted on .
CG-P5, a topical peptide eye drop, met safety and efficacy endpoints for wet age-related macular degeneration, according to a presentation at the American Society of Retina Specialists annual meeting.“When we start thinking about the current demand and what we actually need for patients with wet macular degeneration, there’s a clear need for up to 40% of patients who don’t have
July 17, 2026
3 min watch
Add topic to email alerts
Receive an email when new articles are posted on
Please provide your email address to receive an email when new articles are posted on .

Pegcetacoplan slows photoreceptor and retinal pigment epithelium loss in patients with geographic atrophy only as well as…

MONTREAL — Pegcetacoplan may help slow visual acuity loss in patients with geographic atrophy, according to a study presented at…

DENVER — A real-world analysis showed increased rates of undertreatment and attrition with anti-VEGF injections in patients with…

LAS VEGAS — A VEGF/Ang-2 inhibitor demonstrated faster drying compared with faricimab in patients with diabetic macular edema,…

DENVER — In a phase 1b trial, subretinal delivery of a human stem cell-derived retinal pigment epithelium yielded visual…

ORLANDO — In this video, David A. Eichenbaum, MD, FASRS, discusses late-stage wet age-related macular degeneration assets…